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Abstract
Introduction
This brief report describes the replacement of phentolamine mesylate with an equal amount of chlorpromazine 
HCl in vasoactive drug mixtures used as intracavernous (IC) injection therapy for treating erectile dysfunction 
(ED). Phentolamine, amongst other drugs, had been used in drug injection therapy for the treatment of ED, but 
was replaced as single drug therapy by more effective drugs, such as alprostadil (prostaglandin E1). It has, 
however, still widely been used as alpha-blocking agent in vasoactive drug cocktails. Phentolamine has a syn-
ergistic effect with alprostadil, papaverine and atropine in drug combination cocktails. These injection mixtures 
are very effective for treating ED and are commonly known as bimixtures, trimixtures and quadmixtures. The va-
soactive drug, phentolamine, was withdrawn from the market in South Africa. Chlorpromazine (a phenothiazine) 
was suggested as an alternative alpha-blocking agent to be used in drug cocktails for the IC treatment of ED.
Methods
Three hundred and sixty-four (364) patients were questioned and evaluated during follow-up visits to an ED 
clinic after phentolamine mesylate was replaced with an equal amount of chlorpromazine HCL in their regular IC 
injection preparations. The collected data is based on results from self-administration at home.
Results
No significantly unusual adverse effects or altered efficacy of the new preparations were reported. The pa-
tients noted a change in the colour of the drug mixtures that contain chlorpromazine and papaverine. Despite 
this slight change in colour, the effectiveness of the mixtures remained the same if a use-before date of three 
months was adhered to.
Conclusion
The results indicate that phentolamine mesylate can effectively be replaced with an equal amount of chlor-
promazine HCL in IC drug cocktails for the treatment of ED.
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Materials and Methods 
Three different vasoactive preparations, 
namely a bimixture, trimixture and quad-
mixture, were compounded. The three 
different mixtures were dispensed to 
patients at three different clinics treating 
patients with ED. The sterile mixtures 
were prepared by qualified pharmacists 
under aseptic conditions in a class 100 
laminar airflow cabinet in a class 100 air 
quality clean room environment. The 
drugs were mixed and diluted to the 
correct final concentration with sterile 
normal saline (NaCl 0.9%, Adcock Criti-
cal Care, South Africa).The mixtures that 
were compounded contained exactly 
the same concentration of chlorproma-
zine HCL (Largactil, Aventis Pharma, 
South Africa) instead of the previously 
used phentolamine mesylate (Regitine, 
Novartis, South Africa). The bimixture 
contained alprostadil (Cascade Bio-
chem, Little island, Cork, Ireland) 10 
µg/ml and chlorpromazine HCl 0.4 mg/
ml. The trimixture contained alprostadil 
20 µg/ml, chlorpromazine HCL 1 mg/ml 
and papaverine HCL (Papaverine 60, 
Aspen Pharmacare: Pharma, South 
Africa) 12 mg/ml. The quadmixture 
contained alprostadil 10 µg/ml, chlor-
promazine HCL 1 mg/ml, papaverine 
HCL 12 mg/ml and atropine sulphate 
(Atropine Sulphate-Fresenius Amps, 
Fresenius Kabi, Bodene, South Africa) 
0.15 mg/ml. 
The mixtures were dispensed to patients 
in either 1 or 0.5 millilitre unit dose insu-
lin syringes (BD Micro-Fine Plus, Beck-
ton Dickenson and Company, Franklin 
Lakes, NJ, USA) or in sterile 10 millilitre 
glass multi-dose injection vials (Anchor 
Rand, Johannesburg, South Africa), de-
pending on the patient’s requirements. 
All patients had previously been treated 
with phentolamine mesylate combined 
with the other drug(s) in the same 
mixtures for at least three months or 
longer prior to the changeover to chlor-
promazine HCl mixtures. The patients 
were asked to store the medication in a 
refrigerator in exactly the same way as 
before, to inject exactly the same vol-
ume as before and not to deviate from 
any personal procedures that they have 
been accustomed to with the use of the 
previous preparations. A beyond-use 
date of three months if stored at 5°C was 
maintained. This was done because of 
the limited stability of alprostadil in solu-
tion,17,18 although increased stability of 
compounded IC cocktails have been 
reported after the preparations were 
subjected to a number of freeze-thaw 
cycles.19 The patients were informed 
about the drug substitution. During the 
follow-up visits of the patients to the 
clinics, they were asked to report (yes 
or no) in a simple questionnaire on the 
effectiveness of the drug or on side ef-
fects not previously noted with the phen-
tolamine preparations. The questions 
included (a) burning sensation - not 
previously experienced after injection, 
(b) prolonged or insufficient erections, 
(c) lump formation, (d) effects related 
to abnormal systemic fall in blood pres-
sure, (e) changes in effectiveness of the 
new medication, (f) physical changes in 
the drug preparation itself (e.g. colour, 
viscosity, crystallisation, etc.) and (g) 
satisfaction with the new preparation. 
In the cases where positive answers 
to the questions (yes answer) were 
reported, more information regarding 
those questions and answers were 
asked and noted by the clinician. 
Results
Table I shows the reported effects or 
side effects of compounded chlor-
promazine cocktails.
a.  *Burning sensation - not previously 
experienced after injection.
b. Prolonged or insufficient erection.
c. Lump formation.
d.  Effects related to abnormal systemic 
fall in blood pressure.
e.  Changes in efficacy of the medica-
tion.
f.  Physical changes in the preparation 
itself (e.g. colour, viscosity, crystal-
lisation, etc.).
g.  Satisfaction with the new prepara-
tion.








Positive responses (yes answers) to evaluation questions* 
(a) (b)  (c) (d) (e) (f) (g)
Bimix 916 305 3.0 1 (0.33%) 2 (0.65%) 0 0 2 (0.65%) 0
298 
(97.70%)















A burning sensation caused by IC 
injections that contain alprostadil is a 
common side effect. Only one patient 
(0.33%) in the bimix group reported a 
difference regarding this effect (a). Pro-
longed or insufficient erections (b) were 
reported by two patients (0.65%) using 
bimix, by one patient (3.03%) using the 
trimix and by one patient (3.85%) in the 
quadmix group. No lump formation (c) 
and other effects related to abnormal 
systemic fall in blood pressure (d) were 
reported with any of the preparations. 
Changes in the efficacy of the medica-
tion (e) were reported by two patients 
(0.65%) in the bimix, two (6.06%) in the 
trimix and one (3.85%) in the quadmix 
group. Physical changes in the prepa-
ration (f) were reported by 31 patients 
(93.94%) in the trimix group and 23 
(88.46%) in the quadmix group. Two 
hundred and ninety-eight (97.70%), 29 
(87.88%) and 24 (92.30%) patients in 
the bimix, trimix and quadmix groups 
respectively were satisfied with the new 
preparations (g).
In all cases in which patients (1.10%) 
reported prolonged or insufficient erec-
tions (b), it was due to insufficient erec-
tions rather than prolonged erections. 
All the patients that reported changes 
in medication efficacy (e) (1.37 %) did 
so because of an improvement in the 
effectiveness of the new preparation. A 
colour change (f) in the new preparation 
was reported by 93.94% of patients on 
the trimix preparations and by 88.46% 
of patients on the quadmix prepara-
tions. Both these preparations contain 
chlorpromazine and papaverine. The 
bimix (alprostadil and chlorpromazine) 
remained clear, as with the previous 
phentolamine preparations.
Conclusion
Although the data collected for our 
study was based on self-administration 
at home, our results correlate with those 
obtained in a controlled clinic setting16 
and clearly indicate that phentolamine 
mesylate can effectively be replaced 
with chlorpromazine HCL in IC injection 
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cocktails for the treatment of ED. At 
the same concentration, the efficacy 
and adverse effects are similar to that 
of phentolamine mesylate. No lump 
formation and postural hypotension 
were reported. The change in colour of 
the compounded mixtures containing 
chlorpromazine and papaverine was 
the most noted difference in these 
preparations. The yellowish colour 
remains stable if the preparation is 
stored at 5 °C in the dark for up to three 
months and does not seem to influence 
the effectiveness of the compounded 
mixtures. The effects of long-term use 
of chlorpromazine HCL in IC injections 
and its combination with oral agents still 
needs to be investigated.
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